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OBJECTIVES We investigated if endothelin (ET)-1 and the renin-angiotensin-aldosterone system play a
role in cardiac fibrosis.
BACKGROUND Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are
incompletely understood.
METHODS Four-week-old transgenic (mRen2)27 rat (TGRen2) received for four weeks a placebo, the
mixed ETA/ETB endothelin receptor antagonist bosentan, the angiotensin II type I receptor
(AT-1) antagonist irbesartan, the ETA endothelin receptor antagonist BMS-182874, and a
combined treatment with irbesartan plus BMS-182874. We measured collagen density on
Sirius red–stained serial sections of the left ventricle (LV) with a photomicroscope equipped
with specific software and assessed the gene expression of procollagen 1(I), atrial natriuretic
peptide (ANP), transforming growth factor-beta 1 (TGF1), endothelin converting enzyme,
and ETB receptor.
RESULTS In the placebo group, hypertension was associated with LV hypertrophy and cardiac fibrosis
(LV weight: 4.0  0.3 mg/g body weight; collagen density: 2.21  0.16%), which were all
prevented with irbesartan (2.3  0.1, 1.30  0.13, p  0.001), but not with BMS-182874
(4.0 0.2, 2.41 0.22). Bosentan also prevented fibrosis (1.39 0.18) but not hypertension
and LV hypertrophy (3.38  0.27). Combined irbesartan and BMS-182874 treatment
prevented LV hypertrophy (2.9  0.1) but not fibrosis (2.52  0.16). Collagen density
correlated (r  0.414, p  0.05) with plasma aldosterone levels. In TGRen2 with LV
hypertrophy, the gene expression of ANP and ETB but not that of TGF1 and procollagen
1(I) was increased.
CONCLUSIONS In Ang II–dependent hypertension, cardiac fibrosis was associated with LV hypertrophy and
was hindered by both mixed ETA/ETB blockade and AT-1 blockade. Only the latter
treatment prevented both hypertension and LV hypertrophy. Thus, there is a dissociation
between the mechanisms of cardiac fibrosis and hypertension, which do and do not entail
ET-1, respectively. (J Am Coll Cardiol 2003;41:666–73) © 2003 by the American College
of Cardiology Foundation
Cardiac fibrosis is a relevant clinical problem that will
become even more important with the aging of the popu-
lation and the increased survival of patients with different
cardiac diseases. Compelling evidence indicates that excess
collagen deposition detrimentally affects the functional
properties of the heart by increasing diastolic stiffness,
impairing systolic function, favoring arrhythmias, and ulti-
mately leading to pump failure.
The renin-angiotensin-aldosterone system (RAAS) is
deemed to play a pivotal role in regulating the deposition of
extracellular matrix in the heart and causing cardiac fibrosis.
In vitro experiments on fibroblasts initially showed that
both angiotensin II (Ang II) and aldosterone concentration-
dependently promoted collagen synthesis; in vivo studies in
experimental models of hypertension with either an excess
mineralocorticoid activity or an activated RAAS subse-
quently confirmed these findings (1,2).
The transgenic (mRen2)27 rat (TGRen2) features an
overexpression of the Ren2 transgene in several tissues, with
ensuing increased Ang II concentrations (3); accordingly, it
is regarded as a paradigm of severe Ang II–dependent
hypertension and cardiovascular disease. In the myocar-
dium, the amount of Ren2 messenger ribonucleic acid
(mRNA) correlates not only with the transgene dose (4) but
also with the content of Ang II, which might act in a
paracrine fashion to cause both cardiac hypertrophy and
fibrosis. Thus, the high tissue Ang II levels in the myocar-
dium might interact synergistically with the stress imposed
by the high afterload in stimulating protein synthesis and
cardiomyocyte and fibroblast growth (2). Because cardiac
fibrosis was found to correlate with impaired diastolic
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function more closely than cardiac hypertrophy (5,6), it is
likely to play a major role in impairing cardiac function.
In the adrenal cortex, expression of the Ren2 transgene
and high tissue Ang II (7) lead to enhanced aldosterone
secretion (8) that, along with Ang II (3,9), can enhance
collagen synthesis, thus inducing a progressive collagen
accumulation with aging (10). Nonetheless, it remains
uncertain if and by which mechanisms cardiac fibrosis
occurs in TGRen2 (10,11).
The existence of interactions between the RAAS and
endothelin (ET)-1 (12) suggests an involvement of the
latter in cardiac fibrosis. Angiotensin II activates the tran-
scription of the preproET-1 gene in different cell types of
the heart, including myocytes, vascular smooth muscle, and
endothelial cells (13). Thus, the high cardiac tissue Ang II
content might increase locally the ET-1 synthesis.
Endothelin-1 activates the procollagen I promoter (14) and
collagen synthesis in fibroblasts; it can modulate collagenase
activity, although it is unclear which ET receptor subtype
mediates these effects (15–18). Moreover, ET-1 potently
stimulates, via ETB receptors, aldosterone release (19) and
therefore might increase collagen synthesis via enhanced
aldosterone secretion. Thus, we investigated the deposition
of myocardial collagen and the gene expression of procol-
lagen 1(I), ETB, transforming growth factor-beta 1
(TGF1), endothelin converting enzyme (ECE), and atrial
natriuretic peptide (ANP) in TGRen2, an obvious experi-
mental model in which to test this hypothesis. We also
assessed the effects of selective blockade of the angiotensin
II type I receptor (AT-1), ETA, and ETB receptor subtypes
on myocardial collagen deposition.
MATERIALS AND METHODS
Male heterozygous TGRen2 at age four weeks, after mea-
surement of body weight (BW) and systolic blood pressure
(BP, tail-cuff method), were BW- and BP-matched and
randomly allocated to receive for four weeks any of the
following treatments: a placebo, the mixed ETA/ETB en-
dothelin receptor antagonist bosentan (100 mg/kg BW), the
AT-1 receptor–selective antagonist irbesartan (50 mg/kg
BW), the ETA-selective endothelin receptor antagonist
BMS-182874 (52 mg/kg BW orally), and the combined
treatment of irbesartan (50 mg/kg BW) plus BMS-182874
(52 mg/kg BW orally). These dosages of irbesartan and
ET-1 receptor antagonists were chosen because they were
previously shown to abolish the pressor effect of Ang II and
ET-1, respectively (3). Bosentan was a generous gift of Dr.
Martine Clozel (Actelion Ltd, Allschwil, Switzerland), and
BMS-182874 and irbesartan were generously provided by
Dr. James Powell of Bristol Myers Squibb (Princeton, New
Jersey).
Each treatment was given individually to each rat as a
chocolate-flavored agarose gel tablet. The latter was cut into
pieces of proper size in order to obtain the amount required
to provide each individual rat with its BW-tailored daily
dosage of drug (3). The study protocol and animal handling
followed our institutional guidelines for animal studies and
were previously reported (20). At weekly intervals, we
measured BW and systolic BP levels (by a tail-cuff method,
as the mean value of at least three readings). When the rats
were eight weeks old, they were weighed and euthanized by
cervical dislocation. The hearts were quickly removed and
weighed, then the left ventricle (LV) was rapidly dissected
from atria and right ventricle, weighted, snap-frozen in
isopentane precooled on dry ice, and stored in liquid
nitrogen until analyzed. After removal of the heart and
lungs, blood was collected into heparinized tubes for the
measurement of plasma aldosterone, as reported (3).
Collagen density and types. 5-m equatorial and serial
sections obtained from the LV tissue were stained with
Sirius red (0.5% Sirius red F3BA in saturated picric acid) to
visualize fibrillar collagen. Quantitative analysis was per-
formed blindly by a single examiner (T.M.S.), using a
photomicroscope Leica DM equipped with QWin Standard
Leica Image Software. To minimize operator-dependent
variability, a specific routine was used to automatically
detect chromatic tonalities corresponding to Sirius red–
stained collagen fibrils. Views were randomly selected from
each section. Ten random views were captured and analyzed
for each section at magnification 10, because a pilot study
showed that they represented accurately the entire section.
To estimate perivascular fibrosis, at least one vessel with
external diameter between 50 and 150 m was also included
in 4 of the 10 views considered for each section. All these
measurements were performed on at least four sections for
each rat. We estimated collagen density by measuring in
each field the percent of total surface area pertaining to
fibrillar collagen, identified as specified earlier (21). This
morphometric approach for measurement of fibrillar colla-
gen within the cardiac interstitium was previously validated
(22); collagen density assessed by this technique was also
shown to correlate with hydroxyproline concentration in the
LV (23,24).
For measurements of the media cross-sectional areas of
the cardiac arterioles, sections of four to six arterioles
(ranging between 50 and 250 m in diameter) for each rat
were cut across their transverse axis and examined at 20
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magnification. The aforementioned software was used to
automatically compute all direct measurements.
Polarization microscopy was used to measure strongly
(red-orange) and weakly (greenish-yellow) birefringent fi-
bers in picrosirius-stained sections (25). These fibers
roughly correspond to collagen type I, 1.6 to 2.4 m
diameter-thick, and collagen type III, less than 0.8 m
diameter-thick fibers, respectively (26). Specific routines
were created with the QWin Standard Leica Image Soft-
ware and were used to measure total and red-orange or
greenish-yellow birefringent areas. The latter were ex-
pressed as percent of the total area examined in each section,
as described previously.
Immunohistochemistry to laminin. Serial sections ob-
tained from the LV tissue were also immunostained with a
mouse anti-laminin monoclonal antibody (MAB 1920,
Chemicon International, Temecula, California) in a Ven-
tana Full Nexes IHC Unit (Ventana, Strasbourg, France)
using biotin-streptavidin-conjugated AffiniPure donkey an-
timouse immunoglobulin G (Jackson ImmunoResearch,
ListarFish, Carugate, Italy). The extent of immunostaining
was scored blindly from 1 to 4 by two independent observers.
Gene expression studies. Total RNA was extracted ac-
cording to the Trizol protocol (Gibco-Life Technology,
Grand Island, New York). Gene expression for ETB,
TGF1, ECE, and ANP was assessed by Northern blot
analysis, as described (27). These experiments were carried
out in the Department of Pharmacology and Toxicology of
the Freie University of Berlin.
Gene expression for procollagen 1(I) was measured by
real-time fluorescence reverse transcriptase/polymerase
chain reaction. Primers for this gene (Access code: Z78279)
were selected with Primer3 software: Forward: GGCAA-
CAAAGGAGACACTG, Reverse: CAACACCAT-
CAGCACCAG. The housekeeping gene GAPDH (Ac-
cess code: AF106860) was amplified in parallel with the
following primers: Forward: CCCTTCATTGACCT-
CAACTA, Reverse: GCCAGTGAGCTTCCCGTTCA
and used for normalization purposes. Quantification of
mRNA levels was carried out using a thermal cycler (iCy-
cler, Biorad, Milan, Italy) equipped with an online
fluorescence-based detection system of amplification prod-
ucts. Melting curve analysis was used to confirm the
specificity of the amplification products.
Statistical analysis. Results are expressed as mean SEM.
Comparisons of active treatments with placebo were per-
formed with non-parametric Mann-Whitney U test. Plasma
aldosterone was analyzed after log transformation. To in-
vestigate the relationship between collagen density and
plasma aldosterone or total birefringence, and between
plasma aldosterone and selective red-orange or greenish-
yellow birefringence, we used Pearson correlation coefficient
and a stepwise regression analysis (backward method with
an inclusion cutoff value of 0.05). A p value 0.05 was
considered statistically significant. Analyses were carried out
with the SPSS for Windows statistical package (version
10.0, SPSS Inc., Chicago, Illinois).
RESULTS
BP, heart weight, and plasma aldosterone levels. No
significant differences of BP at baseline and of BW at any
time during the study period between experimental groups
were observed. Starting from the end of the first week of
treatment, the rats on irbesartan showed a markedly lower
BP (p 0.001) compared with the other groups (Fig. 1). At
variance, in the group receiving irbesartan plus BMS-
182874, lower BP values (p  0.01) were recorded only at
the end of the third week compared with the bosentan and
BMS-182874 groups.
At the end of the study period, a significantly lower
weight of the LV was observed in the groups treated with
irbesartan compared with the other groups, with the excep-
tion of irbesartan plus BMS-182874. In the latter group, the
LV weight was lower than in the placebo and BMS-182874
groups (Table 1). The lowest weight of the LV and the
heart in toto was seen in the irbesartan and the highest in
the BMS-182874 group; no significant differences of the
right ventricle weight were found between groups (data not
shown). Plasma aldosterone levels were significantly de-
creased only by irbesartan (Table 1).
Figure 1. Systolic blood pressure (SBP) values in the five experimental
groups before and during the treatment with placebo (open squares),
bosentan (closed circles), irbesartan (closed down triangles), BMS-
182874 (open triangles), and irbesartan plus BMS-182874 (closed up
triangles). Starting from the end of the first week of treatment, SBP was
significantly lower (p  0.001) in the irbesartan group compared with all
other groups. In the irbesartan plus BMS-182874 group, SBP was
significantly (p  0.01) lower only at the end of the third week compared
with the bosentan and BMS-182874 groups.
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Left ventricular collagen. No area of scarring was detected
in the examined fields. Significant differences in collagen
density were found between groups (Fig. 2). Both irbesartan
and bosentan significantly reduced collagen density by 42%
and 37%, respectively. Conversely, both BMS-182874 and
irbesartan plus BMS-182874 significantly increased colla-
gen density compared with either bosentan or irbesartan
(Fig. 3). Similar differences between treatment groups were
seen in perivascular fibrosis (Fig. 2). Collagen density
significantly correlated with plasma aldosterone levels (r 
0.414, p  0.05).
Polarization microscopy showed differences of total bire-
fringence that strikingly mirrored those of collagen density
(Fig. 4); the lowest values being found in the bosentan and
irbesartan groups, and the highest in the irbesartan plus
BMS182874 group. Red-orange fibers showed changes that
paralleled those of collagen density and total birefringence,
whereas greenish-yellow fibers exhibited an opposite behav-
ior (Fig. 4). A correlation was found between total birefrin-
gence and collagen density (r  0.61, p  0.01). Plasma
aldosterone levels correlated (p  0.05) with red-orange
directly (r  0.38) and with greenish-yellow birefringence
inversely (r  0.382).
The media cross-sectional area of the intracardiac arte-
rioles was significantly lower in irbesartan-treated than in
BMS-182874-treated TGRen2.
Immunostaining to laminin. The immunostaining to
laminin was located in the plasma membranes of cardiomy-
ocytes and in the subendothelial lining. Results of the
semiquantitative assessment showed no discernible differ-
ences between experimental groups (Table 1).
Gene expression studies. Results of Northern blots are
summarized in Table 1. The ETB exhibited a significant
decrease with irbesartan compared with BMS-182874. No
significant difference between groups was observed for
mRNA levels of ANP, TGF1, ECE, and procollagen
1(I).
DISCUSSION
One of the major findings of this study, which resolves the
existing controversies (10,11,27–29), is the demonstration
that cardiac fibrosis occurred early (Fig. 1) and was associ-
ated with prominent LV hypertrophy in this model of severe
Ang II–dependent hypertension. The finding of an exclu-
sive increase of LV mass is fully consistent with available
results in 10- to 14-week-old TGRen2 (10,11), whereas
that of an early developing cardiac fibrosis involving both
the interstitium and the perivascular regions is not. In
10-week-old TGRen2, Bishop et al. also found cardiac
fibrosis; in contrast, Flesch et al., on the basis of measure-
ments of hydroxyproline content and a qualitative evalua-
tion of LV sections exposed to trichrome staining for
connective tissue, found no cardiac fibrosis (10,11). It is
always difficult to reconcile divergent results of studies
carried out with different methodologies; however, it is
worth pointing out that the measurement of hydroxyproline
is a rather insensitive tool for the assessment of early cardiac
fibrosis because this amino acid residue entails only a minor
proportion (about 14%) of collagen. This is shown by the
histologic finding of cardiac fibrosis despite no increase of
hydroxyproline content in the LV of young TGRen2 (10).
Furthermore, in our experience the trichrome staining
techniques, which were used in previous studies (10,11) for
visualizing connective tissue, provide quite variable results
and therefore are unsuitable for quantitation purposes. This
is at variance with the Sirius red staining of fibrillar collagen,
which provides accurate and consistent results.
Our findings, with a painstaking operator-independent
quantitative evaluation of collagen density on serial sections
of the LV, fully support the conclusion that fibrillar collagen
deposition occurs at an early stage of cardiac hypertrophy in
the LV of TGRen2 (27).
Polarization microscopy evaluation of the sections dem-
onstrated that Sirius red–stained fibrillar collagen mostly
represents collagen types I and III, as indicated by the close
Table 1. LV Weight, Plasma Aldosterone Levels, Media Cross-Sectional Area of Arterioles, Results of Gene Expression













LV weight (mg/g BW) (NV  1.87  0.01) 4.0  0.3 3.4  0.1 2.3  0.1*† 4.0  0.2 2.9  0.1‡
Plasma aldosterone (pmol/l) (NV  23.2  1.7) 60.1  15.5 52.1  5.2 40.2  6.6§ 50.6  17.0 63.7  16.7
Media cross-sectional area of arterioles (m2) 4493  488 4955  513 3532  355 6218  265 NA
LV ANP/ actin mRNA 0.72  0.10 0.78  0.14 0.16  0.05 1.58  0.79 0.24  0.10
LV ECE/ actin mRNA 4.36  1.52 3.85  0.42 3.46  0.52 4.70  0.35 5.45  0.49
LV ETB/ actin mRNA 3.48  0.35 3.33  0.35 2.45  0.33¶ 5.34  0.72 3.92  0.78
LV TGF1/ actin mRNA 2.30  0.14 2.25  0.09 2.77  0.42 2.91  0.28 2.97  0.32
LV procollagen 1(I)/GAPDH mRNA 0.86  0.05 1.01  0.06 0.83  0.05 1.02  0.05 0.96  0.12
Immunostaining to laminin (arbitrary units) 2.75  0.63 2.33  0.33 2.60  0.40 2.60  0.40 2.75  0.25
Values are expressed as mean  SE; *p  0.0001 versus placebo and BMS-182874; †p  0.003 versus bosentan; ‡p  0.02 versus placebo and BMS-182874; §p  0.05 versus
placebo; p  0.05 versus BMS-182874; ¶p  0.005 versus BMS-182874. mRNA expression for each gene was normalized for the housekeeping gene  actin or GAPDH in
Northern blots and RT-PCR experiments, respectively.
ANP  atrial natriuretic peptide; BW  body weight; ECE  endothelin converting enzyme; GAPDH  glyceraldehyde-3-phosphate dehydrogenase; LV  left ventricle;
mRNA  messenger ribonucleic acid; NA  not available; NV  normal values obtained in a series of 12-week-old normotensive Sprague-Dawley rats, shown for comparison;
TGF1  transforming growth factor beta 1.
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correlation between collagen density and total birefringence
in each section. Furthermore, accumulation of fibrillar
collagen was largely accounted for by thick, strongly bire-
fringent red-orange fibers that correspond to a large extent
to collagen type I. In contrast, thin, weakly birefringent
greenish fibers, mostly entailing collagen type III, were
predominantly found in those hearts that did not show overt
cardiac fibrosis, such as those of the irbesartan and bosentan
groups. The relative abundance of these types of fibers and
collagens might be of utmost importance in determining the
diastolic properties of the heart. Of note, we did not find
any differences in the amount of immunostaining to laminin
between our experimental groups, suggesting that changes
of this basement membrane protein do not play a major role
in cardiac fibrosis.
Mechanisms of cardiac fibrosis. We used a combined
strategy based on gene expression experiments and on
pharmacologic intervention with drugs capable of providing
specific blockade of the AT-1 or of the ETA and ETB
receptors to gain information on their potential involvement
and on the mechanisms underlying cardiac fibrosis. Our
gene expression experiments showed an increased expres-
sion of ANP mRNA and a significant correlation between
ANP mRNA and LV mass index, which accord well with
previous findings (11,21), as well as with the contention that
this gene is a marker of cardiac hypertrophy. We also found
an increase of ETB mRNA in the groups with overt LV
hypertrophy (Table 1). The ETB mRNA correlated signif-
icantly with the media cross-sectional area of the intracar-
diac arterioles (r  0.636, p  0.001) and with LV mass
index. Accordingly, an increased ETB gene expression,
which might therefore be due to an increase in vascular
endothelial cells, could also be a marker of cardiac hyper-
trophy. The expression of the TGF1 gene was previously
found to occur with the development of cardiac hypertro-
phy, but only early and transiently (21,30). Hence, it is not
surprising that its expression was not found to be enhanced
under the chronic conditions of this study. The expression
Figure 2. Microphotographs of left ventricular myocardium stained with the collagen-specific dye Sirius red. Collagen fibers appear as red structures, and
myocytes and intramyocardial vessels are yellow (magnification 40). A diffuse interstitial and a marked perivascular fibrosis is evident in placebo-treated
eight-week-old TGRen2 (A). Irbesartan (B) and bosentan (C) treatment for four weeks resulted in a marked reduction of fibrosis, both in the interstitium
and perivascularly. No effect of treatment with the ETA receptor antagonist BMS-182874 (D) was seen. The combined treatment with irbesartan plus
BMS-182874 (E) did not reduce cardiac fibrosis compared with placebo and with BMS-182874 alone.
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of procollagen 1(I) did not reflect the marked differences
in collagen density that were seen between groups. Thus, it
might be that the early activation of Ang II production due
to the transgene expression from birth and the ensuing
recruitment of the ET-1 system stimulate collagen synthesis
only early on and that a blunted collagen-degrading activity
may account for extracellular matrix deposition later on. We
could not measure the activity of enzymes involved in
collagen degradation, therefore this hypothesis remains to
be conclusively proven.
We found that the AT-1 receptor antagonist irbesartan
prevented both hypertension and cardiac hypertrophy. It has
Figure 3. Left ventricular collagen density, expressed as percent of the total area pertaining to fibrillar collagen (as visualized by the Sirius red staining) and
measured by videodensitometry, was significantly decreased in bosentan- and irbesartan-treated eight-week-old TGRen2 compared with both age- and
gender-matched placebo-treated TGRen2 and with BMS-182874 or BMS-182874  irbesartan. The BMS-182874, either alone or combined with
irbesartan, did not reduce collagen density compared with placebo.
Figure 4. The bar graph shows total birefringence (left bars of each group) and the ratio of red-orange to greenish-yellow fibers (right bars of each group)
of Sirius red–stained sections of the LV of eight-week-old TGRen2, assessed with polarization microscopy. Total birefringence is expressed as percent of
the total area pertaining to the sum of red-orange and greenish-yellow fibers, which roughly correspond to collagen type I and III, respectively. Total
birefringence and the ratio of red-orange to greenish-yellow fibers were lower in bosentan-treated TGRen2 compared with placebo. The TGRen2 receiving
irbesartan  BMS-182874 showed a significantly higher total birefringence compared with both bosentan- and irbesartan-treated TGRen2.
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recently been contended that pressure overload is the only
factor responsible for development of LV hypertrophy and
cardiac fibrosis in TGRen2 (10). This proposal has been
contradicted by a reevaluation of the data obtained with
amlodipine in the same study (31) and is not supported by
the present results with the different receptor antagonists.
Our regression analysis showed that plasma aldosterone,
besides BP levels, significantly predicted collagen density,
thus supporting the view that there are multiple determi-
nants of cardiac fibrosis. This conclusion agrees also with
findings in another model of hypertension caused by inhi-
bition of nitric oxide synthesis, where bosentan prevented
the severity of glomerular and interstitial fibrosis in the
kidney (14), even despite that there was no effect on the
development of hypertension (32).
ET-1 and cardiac fibrosis. The role of ET-1 in Ang
II–dependent hypertension remains unclear because there
are studies implicating ET-1 in models of Ang II infusion
(33,34) and others contradicting this contention in models
with enhanced synthesis of endogenous Ang II, such as the
2 kidney 1 clip (2K1C) and the TGRen2 models (3,12).
Nonetheless, in these latter conditions, as well as in post-
myocardial infarction models of congestive heart failure
(35), the ET system would appear to play a role in the
progression of cardiovascular damage, including cardiac
fibrosis and LV dysfunction (27). This detrimental role of
ET-1 is deemed to be even more important in models with
excess mineralocorticoid activity, where the vascular synthe-
sis of ET-1 is enhanced (1). In deoxycorticosterone acetate
(DOCA)–salt hypertensive rats, an ETA-selective antago-
nist prevented cardiac fibrosis and activation of procollagen
1(I) synthesis (21), thus implicating the ETA receptor
subtype. Experiments in 2K1C rat with the ETA antagonist
BQ-123 and with the ETB antagonist IRL-1038 led to the
hypothesis that the ETB subtype might mediate cardiac
fibrosis when the RAAS is activated (36). However, the
implication of the ETB receptor in cardiac fibrosis remained
to be conclusively demonstrated (37), because IRL-1038
was publicly retreated because of its inconsistent selectivity
for the ETB receptor by those who synthesized it (38).
The present findings of prevention of cardiac fibrosis with
the mixed ETA/ETB antagonist bosentan, but not with the
ETA-selective antagonist BMS-182874, are consistent with
previous findings in chronic heart failure (35) and point to
the ETB as mediator of cardiac fibrosis in TGRen2. A role
of ETB receptors in collagen deposition was previously
shown in the liver (15,18). In addition, in chronic heart
failure ETB blockade reduced cardiac fibrosis despite the
lack of hemodynamic effects (18,39). The present findings
in TGRen2 are consistent with this observation and shed
new light on the role of this receptor subtype in cardiac
fibrosis.
It must be acknowledged that our pharmacologic exper-
iments provided evidence for a role of ETB receptors in
cardiac fibrosis by “subtraction,” i.e., by comparison of a
mixed ETA/ETB with an ETA-selective antagonist. How-
ever, this is due to the current unavailability of an ETB-
selective antagonist for chronic in vivo studies. Furthermore,
our findings of an increased expression of the ETB gene in
the heart of TGRen2 treated with the ETA-selective an-
tagonist that exhibited marked cardiac fibrosis, compared
with all other groups (Table 1), are consistent with a role of
ETB receptors in cardiac fibrosis.
ETB receptor subtype, cardiac fibrosis, and aldosterone
synthesis. Based on the fact that the correlation between
cardiac ETB receptor gene expression and collagen density
was weak and not significant, we would like to suggest,
however, an alternative explanation, which does not postu-
late changes of ETB receptors in the heart. Endothelin-1
acts as a potent secretagogue of aldosterone via ETB
receptors (19,40), and compelling evidence implicates both
aldosterone and Ang II in cardiac fibrosis (2). Thus, it
might be that the major mechanism leading to cardiac
fibrosis entails an Ang II- and ET-1-driven stimulation of
aldosterone secretion. The beneficial effect of bosentan and
the lack of effect of BMS-182874 could be explained on this
ground. The predominant perivascular distribution of car-
diac fibrosis and the significant correlation between collagen
density and plasma aldosterone levels (Fig. 2) also support a
major role of blood-borne aldosterone. This contention
might also reconcile the present results with those obtained
with A-127722, an ETA-selective antagonist that lowered
BP and prevented cardiac fibrosis in DOCA–salt hyperten-
sive rats (21). In this latter model, the secretagogue effect of
ET-1 on aldosterone is likely to be negligible because of the
concomitant suppression of the RAAS induced by the
exogenously administered salt and DOCA. In addition, the
lowering of BP seen with A-127722 made it difficult to
attribute the prevention of cardiac fibrosis only to ETA. We
hypothesize that the relative importance of ETA and ETB
receptors in causing cardiac fibrosis could markedly differ
between experimental models, depending on the prevailing
degree of activation of the RAAS and on the concomitant
changes in BP. Thus, development of cardiac fibrosis in
TGRen2 is likely to derive from a synergistic interaction of
the RAAS and ET system. Results in another double
transgenic model of severe hypertension and cardiac hyper-
trophy characterized by activation of RAAS support this
view (41). The clinical implications of these findings for the
prevention or progression of cardiac fibrosis with ET
antagonists in patients with congestive heart failure, who
might have an activated RAAS, are obvious.
In conclusion, the AT-1-selective antagonist irbesartan
prevented hypertension, cardiac hypertrophy, and cardiac
fibrosis in TGRen2. The mixed ETA/ETB antagonist
bosentan, but not an ETA-selective antagonist, also hin-
dered cardiac fibrosis despite having no effect on BP and
cardiac hypertrophy. Both irbesartan and bosentan corrected
the secondary hyperaldosteronism; furthermore, plasma al-
dosterone levels correlated significantly with collagen den-
sity in the LV myocardium. Thus, collectively these results
indicate that although cardiac hypertrophy and cardiac
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fibrosis go hand in hand, the mechanisms regulating the two
processes differ and could be differentially modulated phar-
macologically.
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